Monitor for impending FDA guidance on psychedelic drug development, which could provide regulatory clarity for the sector. Silo's own clinical progress on SPC-15 or SP-26 would be a more direct catalyst than general industry news.
Price Chart
Executive Summary
Silo Pharma issued a press release highlighting recent U.S. federal actions supporting psychedelic therapeutics, including EVIDENT program awards, FDA IND clearance for noribogaine, and priority vouchers. The release is a general industry commentary without company-specific financial data or catalysts, making it a low-impact event for Silo's stock.
Key Facts
- ARPA-H announced initial EVIDENT program awardees including Johns Hopkins University focused on psychedelic science.
- FDA granted IND clearance to DemeRx NB for noribogaine targeting alcohol use disorder.
- FDA issued three Commissioner's National Priority Vouchers to Compass Pathways, Usona Institute, and Transcend Therapeutics.
- Final FDA guidance for psychedelic drug development expected imminently.
- Silo Pharma's pipeline includes SPC-15 (PTSD), SP-26 (fibromyalgia/chronic pain), and preclinical Alzheimer's assets.
Financial Impact
No financial impact disclosed; Silo Pharma is developmental-stage with no revenue.
Risk Factors
- Silo Pharma has a very small market cap ($7M) and no approved products, making it highly speculative.
- Positive federal sentiment may not translate into near-term commercial success or funding for Silo.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3283848 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 8-K | $1.20 | awaiting T+60 | — | $1.14 (−4.59%) |
Oct 2, 2026 24d ago | 8-K | $1.49 | awaiting T+60 | — | $1.14 (−23.16%) |
Sep 18, 2026 5w ago | Press Release | $1.84 | awaiting T+60 | — | $1.14 (−37.78%) |
Aug 7, 2026 11w ago | EFFECT | $3.74 | awaiting T+60 | — | $1.14 (−69.35%) |
Jul 14, 2026 15w ago | Press Release | $5.13 $1.44 | ▼ −71.93% | ▼ −75.31% | $1.14 (−77.68%) |
Jun 30, 2026 17w ago | DEFA14A | $6.21 $1.77 | ▲ +71.50% | ▲ +75.06% | $1.14 (+81.56%) |
Jun 3, 2026 20w ago | 8-K | $6.11 $2.54 | ▼ −58.43% | ▼ −60.31% | $1.14 (−81.26%) |
Jun 1, 2026 21w ago | 8-K | $4.99 $2.59 | ▼ −48.09% | ▼ −49.32% | $1.14 (−77.05%) |
Apr 29, 2026 25w ago | Press Release | $6.74 $4.47 | ▼ −33.63% | ▼ −37.74% | $1.14 (−83.00%) |
Apr 22, 2026 26w ago | Press Release | $7.11 $4.70 | ▼ −33.90% | ▼ −38.91% | $1.14 (−83.90%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers